PIK3CA V955G
|
Colorectal Adenocarcinoma
|
PIK3CA V955G
|
Colorectal Adenocarcinoma
|
cetuximab Resistant: C3 – Early Trials
|
cetuximab Resistant: C3 – Early Trials
|
ALK fusion
|
Colorectal Adenocarcinoma
|
ALK fusion
|
Colorectal Adenocarcinoma
|
ceritinib Sensitive: C3 – Early Trials
|
ceritinib Sensitive: C3 – Early Trials
|
KRAS mutation
|
Colorectal Adenocarcinoma
|
KRAS mutation
|
Colorectal Adenocarcinoma
|
ceritinib Resistant: C3 – Early Trials
|
ceritinib Resistant: C3 – Early Trials
|
EWSR1 mutation
|
Colorectal Adenocarcinoma
|
EWSR1 mutation
|
Colorectal Adenocarcinoma
|
sintilimab + fruquintinib Resistant: C3 – Early Trials
|
sintilimab + fruquintinib Resistant: C3 – Early Trials
|
PD-L2 overexpression
|
Colorectal Adenocarcinoma
|
PD-L2 overexpression
|
Colorectal Adenocarcinoma
|
PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical
|
PD-L1 inhibitor + PD-L2 inhibitor Sensitive: D – Preclinical
|
KRAS G13D
|
Colorectal Adenocarcinoma
|
KRAS G13D
|
Colorectal Adenocarcinoma
|
ASN007 Sensitive: D – Preclinical
|
ASN007 Sensitive: D – Preclinical
|
APC mutation
|
Colorectal Adenocarcinoma
|
APC mutation
|
Colorectal Adenocarcinoma
|
ST316 Sensitive: D – Preclinical
|
ST316 Sensitive: D – Preclinical
|